GlassScriptPhysician profile
Jacqueline M Champlain
NPI 1497049209
$129,620.21
in general payments reported to CMS, 2019-2025
34 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,372 · 2020: $12K · 2021: $27K · 2022: $49K · 2023: $11K · 2024: $9,240 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $3,954 · Food and Beverage: $1,764 · Consulting Fee: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,675.00 |
| Travel and Lodging | $3,954.24 |
| Food and Beverage | $1,763.60 |
| Consulting Fee | $1,316.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $115,105.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $11,267.34 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.58 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $328.46 | 2021-2023 | Trelegy Ellipta |
| Gilead Sciences, INC. | $310.52 | 2019-2023 | |
| Lilly USA, LLC | $308.56 | 2022-2025 | Mounjaro, Trulicity, Reyvow |
| Abbvie INC. | $235.10 | 2022-2023 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $228.57 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $160.80 | 2022-2023 | Farxiga |
| Exact Sciences Corporation | $143.43 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $143.01 | 2021-2022 | |
| Abbott Laboratories | $103.37 | 2019-2023 | Freestyle Libre 3, Proclaim |
| Pfizer INC. | $101.89 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $85.14 | 2022 | |
| Amgen INC. | $83.47 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $83.33 | 2023 | |
| Jazz Pharmaceuticals INC. | $49.51 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $47.52 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $45.13 | 2022-2025 | Zoryve |
| Optinose US, INC. | $37.11 | 2023 | |
| Bausch Health US, LLC | $33.92 | 2022 | |
| Tactile Systems Technology INC | $31.50 | 2019 | |
| Idorsia Pharmaceuticals US INC | $29.58 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $24.00 | 2025 | Aptima |
| Antares Pharma, INC. | $21.99 | 2023 | Tlando, Xyosted, Nocdurna |
| Array Biopharma INC | $19.92 | 2023 | Prevnar 20, Comirnaty, Paxlovid |
| Organon LLC | $17.10 | 2022 | |
| Horizon Therapeutics Plc | $16.88 | 2022 | |
| Merck Sharp & Dohme LLC | $16.19 | 2022 | |
| Shield Therapeutics INC | $15.61 | 2022 | |
| Viiv Healthcare Company | $15.37 | 2023 | Apretude |
| Millicent US INC | $14.36 | 2025 | Femlyv |
| Acerus Pharmaceuticals Corporation | $13.59 | 2022 | |
| Allergan, INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Champlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.